# Cancer
What the story reports
The piece centers memory and action. Though RJ has died, his mother continues to advocate in his name—raising awareness, supporting other families, and keeping the memory of the children alive by saying their names.
A concrete example: Juliana's case
One family shared in detail: Juliana, age 4 in late 2021, developed fevers, appetite loss, extreme sleepiness, and leg pain that was first mistaken for growing pains. When pallor prompted bloodwork, results led to an urgent trip to Texas Children's on December 29. She was diagnosed with B-cell acute lymphoblastic leukemia (ALL) and admitted to the ICU with dangerously low hemoglobin, requiring multiple transfusions.
Much of Juliana's care occurred outpatient, but she had unexpected readmissions and hard days. Her family enrolled her in an immunotherapy clinical trial with continuous treatments lasting between two and 28 days. About a year after she completed treatment, that therapy received FDA approval and became standard of care for B-cell leukemia. After two and a half years of treatment, Juliana rang the cancer bell in March 2024 and returned to a more typical childhood routine as a fourth-grader.
Themes that matter to families
- Treatment is lengthy and disruptive. Even when care is outpatient, families face repeated hospital stays, transfusions, and clinical procedures.
- Clinical trials can bring hope and later broader benefits when successful therapies are approved.
- Grief continues after death. Parents who lose a child often channel their experience into advocacy and memory work.
Call to action for September
The writer frames September as Childhood Cancer Awareness Month and asks readers to do three practical things: remember the children who fought, listen to the families who live with these stories, and advocate for continued support and research. Saying each child's name is presented as a concrete practice to keep memory and momentum alive.
The piece aims to move readers beyond the gold ribbon symbol to the lived realities—treatment timelines, clinical trial journeys, the social networks formed in hospital corridors, and the lifelong emotional consequences for families.